+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Congestive heart failure during induction with anthracycline-based therapy in patients with acute promyelocytic leukemia



Congestive heart failure during induction with anthracycline-based therapy in patients with acute promyelocytic leukemia



Journal of Community and Supportive Oncology 12(11): 390-393



Acute promyelocytic leukemia (APL) is a highly curable malignancy. However, 30% of patients die during therapy induction from bleeding, differentiation syndrome (DS), and/or infection. Recommendations suggest that congestive heart failure (CHF) is a presenting feature of DS. To assess the incidence of CHF during induction in patients with APL. A retrospective chart review was performed of patients diagnosed with APL from December 2004 to July 2013 and managed at Georgia Regents University Cancer Center. Baseline and follow-up ejection fractions (EF) were recorded and patients with a drop in EF during the induction period were evaluated. Of the 40 evaluable patients, 37 received idarubicin-based chemotherapy. 16 of the 37 patients had a repeat ECHO for suspected cardiomyopathy, and 6 of the 16 patients (37.5%) demonstrated a decrease in EF (absolute drop, 10%-35%). The cardiac function recovered completely in 4 patients and partially in 1 patient. Gender, history of hypertension, and body mass index did not seem to correlate with incidence of CHF. The patient population is very small given the rarity of the disease. Present practice patterns do not routinely address CHF in the differential diagnosis. Patients with APL are at risk for cardiac toxicity for a number of reasons, including cytokine storm and inflammatory state, use of anthracyclines, and DS. The clinical presentation of DS most commonly involves dyspnea and fluid retention, which are also symptoms of heart failure. Prompt cardiac evaluation should be undertaken to rule out CHF in APL patients who are going to receive an anthracycline-based therapy, because early intervention may result in an improved outcome.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057491816

Download citation: RISBibTeXText

PMID: 25856011


Related references

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Annals of Hematology 93(12): 2001-2010, 2015

Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. Journal of Clinical Oncology 28(24): 3872-3879, 2010

Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older. Leukemia Research 30(4): 503-506, 2005

Clinico-biological features of 30 patients with acute promyelocytic leukemia and response to combination induction chemotherapy with all-trans retinoic acid and anthracycline. Medical Oncology 17(4): 301-306, 2000

Outcome of Patients with Acute Promyelocytic Leukemia Failing to Treatment with All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy. Blood 100(11): Abstract No 1331, November 16, 2002

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10): 3315-3324, 1999

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115(25): 5137-5146, 2010

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 117(6): 1799-1805, 2011

CNS relapse in a low risk acute promyelocytic leukemia patient treated with ATRA-based regimen: is there a role for prophylactic CNS therapy in acute promyelocytic leukemia?. Indian Journal of Hematology and Blood Transfusion 25(3): 118-119, 2009

Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Circulation 99(23): 2993-3001, 1999

An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. Leukemia and Lymphoma 2018: 1-6, 2018

Anthracycline-induced congestive heart failure in two pediatric leukemia cases and long term follow-up. Pediatric Hematology and Oncology 5(3): 245-251, 1988

Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure. Annals of Hematology 94(3): 501-503, 2015

High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study. Journal of Hematology and Oncology 10(1): 30, 2017

Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi 30(7): 440-442, 2011